a Health Policy Research Center, Shiraz University of Medical Sciences , Shiraz , Iran.
b Health Policy Research Center, Institute of Health, Student Research Committee, Shiraz University of Medical Sciences , Shiraz , Iran.
Crit Rev Food Sci Nutr. 2019;59(11):1753-1766. doi: 10.1080/10408398.2018.1427044. Epub 2018 Feb 2.
This systematic review and meta-analysis of randomized controlled trials (RCTs) was performed to summarize the effect of ginger intake on weight loss, glycemic control and lipid profiles among overweight and obese subjects. We searched the following databases through November 2017: MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. The relevant data were extracted and assessed for quality of the studies according to the Cochrane risk of bias tool. Data were pooled using the inverse variance method and expressed as Standardized Mean Difference (SMD) with 95% Confidence Intervals (95% CI). Heterogeneity between studies was assessed by the Cochran Q statistic and I-squared tests (I). Overall, 14 studies were included in the meta-analyses. Fourteen RCTs with 473 subjects were included in our meta-analysis. The results indicated that the supplementation with ginger significantly decreased body weight (BW) (SMD -0.66; 95% CI, -1.31, -0.01; P = 0.04), waist-to-hip ratio (WHR) (SMD -0.49; 95% CI, -0.82, -0.17; P = 0.003), hip ratio (HR) (SMD -0.42; 95% CI, -0.77, -0.08; P = 0.01), fasting glucose (SMD -0.68; 95% CI, -1.23, -0.05; P = 0.03) and insulin resistance index (HOMA-IR) (SMD -1.67; 95% CI, -2.86, -0.48; P = 0.006), and significantly increased HDL-cholesterol levels (SMD 0.40; 95% CI, 0.10, 0.70; P = 0.009). We found no detrimental effect of ginger on body mass index (BMI) (SMD -0.65; 95% CI, -1.36, 0.06; P = 0.074), insulin (SMD -0.54; 95% CI, -1.43, 0.35; P = 0.23), triglycerides (SMD -0.27; 95% CI, -0.71, 0.18; P = 0.24), total- (SMD -0.20; 95% CI, -0.58, 0.18; P = 0.30) and LDL-cholesterol (SMD -0.13; 95% CI, -0.51, 0.24; P = 0.48). Overall, the current meta-analysis demonstrated that ginger intake reduced BW, WHR, HR, fasting glucose and HOMA-IR, and increased HDL-cholesterol, but did not affect insulin, BMI, triglycerides, total- and LDL-cholesterol levels.
本系统评价和荟萃分析纳入了随机对照试验（RCTs），旨在总结生姜摄入对超重和肥胖人群体重减轻、血糖控制和血脂谱的影响。我们通过 2017 年 11 月检索了以下数据库：MEDLINE、EMBASE、Web of Science 和 Cochrane 对照试验中心注册库。根据 Cochrane 偏倚风险工具提取相关数据并评估研究质量。使用Inverse Variance 方法汇总数据，并以 95%置信区间（95%CI）表示标准化均数差（SMD）。通过 Cochran Q 统计量和 I-squared 检验（I²）评估研究间的异质性。总体而言，共有 14 项研究纳入荟萃分析。我们的荟萃分析纳入了 14 项 RCTs 共 473 名受试者。结果表明，生姜补充剂可显著降低体重（BW）（SMD-0.66；95%CI，-1.31，-0.01；P=0.04）、腰臀比（WHR）（SMD-0.49；95%CI，-0.82，-0.17；P=0.003）、臀围比（HR）（SMD-0.42；95%CI，-0.77，-0.08；P=0.01）、空腹血糖（SMD-0.68；95%CI，-1.23，-0.05；P=0.03）和胰岛素抵抗指数（HOMA-IR）（SMD-1.67；95%CI，-2.86，-0.48；P=0.006），并显著升高高密度脂蛋白胆固醇（HDL-cholesterol）水平（SMD0.40；95%CI，0.10，0.70；P=0.009）。我们发现生姜对体重指数（BMI）（SMD-0.65；95%CI，-1.36，0.06；P=0.074）、胰岛素（SMD-0.54；95%CI，-1.43，0.35；P=0.23）、甘油三酯（SMD-0.27；95%CI，-0.71，0.18；P=0.24）、总胆固醇（SMD-0.20；95%CI，-0.58，0.18；P=0.30）和低密度脂蛋白胆固醇（SMD-0.13；95%CI，-0.51，0.24；P=0.48）没有不良影响。总的来说，目前的荟萃分析表明，生姜摄入可降低 BW、WHR、HR、空腹血糖和 HOMA-IR，升高 HDL-cholesterol，但不影响胰岛素、BMI、甘油三酯、总胆固醇和 LDL-cholesterol 水平。
